A Phase 3 interventional study of Chamomile (Matricaria recutita) in Generalized Anxiety Disorder, sponsored by University of Pennsylvania. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-07-06.
Sponsored by University of Pennsylvania · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.
Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 82nd largest by enrollment of the 234 interventional ones that give a count, is one of 12 that started in 2010, is one of 45 in phase 3, and was the 85th registered.
518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.
Browse Generalized Anxiety Disorder studies →38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:
Virginia Polytechnic Institute and State University · Sites in United States
Ages 18–65
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18+
Intra-Cellular Therapies, Inc. · Sites in United States
Ages 18+
BTL Industries Ltd. · Sites in United States
Ages 22+
Intra-Cellular Therapies, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 88 Generalized Anxiety Disorder studies recruiting now, 32 (36%) set no upper age limit and 54 (61%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
265 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 32 · Phase 3 51 · Phase 4 28
First in 1991; this study’s year is marked. 12 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.
Median enrollment 90 across the 234 interventional studies, 220 across the 28 observational. Of the 199 that completed or were terminated, 90 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 265 have an industry lead sponsor. The 10 most frequent:
University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 229 are open to participants now.
Of its 160 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.
University of Pennsylvania has 7 studies filed under Generalized Anxiety Disorder — fewer than ten, so there is no comparison to draw.
20 of the studies in Generalized Anxiety Disorder with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07123467Phase 3Wayne State UniversityCannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder | 2027-08-31 |
| NCT06846320AbbVieStudy to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | 2026-11 |
| NCT06723158Boston UniversityOral Surgery Virtual Reality Glasses Study | 2026-12 |
| NCT04557891University of California, Los AngelesLow-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD) | 2026-12 |
| NCT05467683Jasper A. SmitsCO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy | 2026-12-01 |
Add all 20 to your calendar (.ics) → With an account.
Among the 265 studies in Generalized Anxiety Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prior research has shown that chamomile may be an effective, short-term anti-anxiety treatment. This study will examine the initial and long-term benefits of chamomile extract therapy for the prevention of recurrent anxiety disorder.
Anxiety disorders are among the most common psychiatric conditions. They affect up to 25% of the US adult population. Generalized anxiety disorder (GAD) is a chronic, recurrent form of the disorder. Although benzodiazepines and serotonin reuptake inhibitors have become the mainstay therapy of GAD, these drugs are often associated with unwanted side effects, habituation, and withdrawal symptoms. Many individuals decline using conventional drug therapy for financial, cultural, or personal reasons such as the stigma of mental illness. As a result, many individuals will seek alternative therapy for their anxiety symptoms. The identification of effective alternative therapies for GAD would be of particular relevance. Among alternative therapies for anxiety, chamomile has been used as a traditional herbal medicine for its calming effect. It is well tolerated and demonstrates pharmacological activity in animal models of anxiety. Despite its widespread use and availability, there has been only one clinical trial of chamomile safety and efficacy in GAD. The current application seeks to build upon the results of that prior chamomile study. In that 8-week, double-blind, placebo-controlled trial, we found a significant superiority of chamomile (vs. placebo) in reducing GAD symptoms. We also found chamomile to be exceedingly well tolerated (vs. placebo). The current application seeks to extend these promising preliminary results by conducting a randomized, double-blind, parallel group, placebo-substitution, long-term safety and efficacy study of chamomile in preventing GAD relapse. For specific aim #1 we will ask: "Does long-term chamomile therapy (vs. placebo) prolong the time to relapse of anxiety symptoms following recovery from GAD?" To answer this question, 180 patients with moderate to severe GAD will receive open-label chamomile extract 500-1,500 mg daily for 8 weeks. Responders to chamomile, who remain well for 4 additional weeks of consolidation therapy, will be randomized to double-blind continuation therapy with chamomile 500-1,500 mg daily or placebo for an additional 26 weeks. We hypothesize that continuation chamomile therapy will result in a prolonged time to relapse (vs. placebo). For specific aim #2 we will ask: "What is the relative safety and tolerability of long-term chamomile therapy (vs. placebo) in patients who have recovered from GAD?" To answer this question, we will examine the following outcome measures: (i) the proportion of patients in each treatment condition who relapse; (ii) the frequency, severity, and duration of treatment-emergent adverse events; (iii) the frequency of discontinuation symptoms during initial double-blind therapy; and, (iv) the frequency of early study discontinuation. We hypothesize that chamomile therapy will result in a lower proportion of anxiety relapses and a lower study discontinuation rate (vs. placebo). We further hypothesize that chamomile therapy will result in a similar frequency of discontinuation symptoms and treatment-emergent adverse events (vs. placebo).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pharmaceutical grade oral chamomile extract.
Drug: Chamomile (Matricaria recutita)
Pharmaceutical grade lactose monohydrate.
Drug: Chamomile (Matricaria recutita)
500 mg 3 times daily
Also known as: Chamomile
Time to Relapse in Each Treatment Condition.
The primary outcome was time to relapse during continuation therapy, analyzed using Cox proportional hazards. Relapse is dichotomously defined as an increase in CGI/S (a clinician-rated global measure of anxiety's severity) score from ≤ 3 (at study visit 6) to ≥ 4 (on two consecutive scheduled or unscheduled study visits ≥ 2 weeks apart) plus meeting DSM IV-TR criteria for GAD (minus the 6-month time criterion).
Time frame: 26 weeks
The Proportion of Subjects in Each Treatment Condition Who Relapse.
The proportion of subjects in each treatment condition who relapsed after randomization
Time frame: 26 weeks
Frequency, Severity, and Duration of Treatment-emergent Adverse Events.
We will report the frequency, severity, and duration of treatment-emergent adverse events by treatment arm.
Time frame: 26 weeks
Frequency of Discontinuation Symptoms at the Start of Double-blind Therapy in Each Treatment Condition.
Discontinuation emergent signs and symptoms checklist (DESS) is a patient-rated measure of the presence and severity of discontinuation symptoms occurring after medication discontinuation. %
Time frame: 26 weeks
Frequency of Early Study Discontinuation in Each Treatment Condition.
This is the # of subjects who discontinued the study during randomization phase due to other reasons.
Time frame: 26 weeks
| Milestone | Chamomile Extract | Placebo |
|---|---|---|
| Started | 46 | 47 |
| Completed | 35 | 29 |
| Not completed | 11 | 18 |
| Withdrew: Relasped-reached end point | 7 | 12 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Lost to follow-up | 3 | 4 |
The primary outcome was time to relapse during continuation therapy, analyzed using Cox proportional hazards. Relapse is dichotomously defined as an increase in CGI/S (a clinician-rated global measure of anxiety's severity) score from ≤ 3 (at study visit 6) to ≥ 4 (on two consecutive scheduled or unscheduled study visits ≥ 2 weeks apart) plus meeting DSM IV-TR criteria for GAD (minus the 6-month time criterion).
| weeks | Chamomile Extract | Placebo |
|---|---|---|
| Time to Relapse in Each Treatment Condition. | 11.4 ± 8.4 | 6.3 ± 3.9 |
The proportion of subjects in each treatment condition who relapsed after randomization
| Participants | Chamomile Extract | Placebo |
|---|---|---|
| The Proportion of Subjects in Each Treatment Condition Who Relapse. | 7 | 12 |
We will report the frequency, severity, and duration of treatment-emergent adverse events by treatment arm.
| Participants | Chamomile Extract | Placebo |
|---|---|---|
| Frequency, Severity, and Duration of Treatment-emergent Adverse Events. | 8 | 9 |
Discontinuation emergent signs and symptoms checklist (DESS) is a patient-rated measure of the presence and severity of discontinuation symptoms occurring after medication discontinuation. %
| Participants | Chamomile Extract | Placebo |
|---|---|---|
| # of subject had no new symptoms after randomizat | 31 | 33 |
| # of subject had >=1 new symptom after randomizati | 14 | 11 |
This is the # of subjects who discontinued the study during randomization phase due to other reasons.
| Participants | Chamomile Extract | Placebo |
|---|---|---|
| # Lost to Follow-up | 3 | 4 |
| # withdrawn due to non-compliance | 1 | 2 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Chamomile Extract | — | 0/46 (0%) | 8/46 (17.4%) |
| Placebo | — | 0/47 (0%) | 9/47 (19.1%) |
| Event | Chamomile Extract | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 3/46 | 0/47 |
| Dry mouthGeneral disorders | 2/46 | 0/47 |
| taste perversionProduct Issues | 1/46 | 2/47 |
| BruisingSkin and subcutaneous tissue disorders | 0/46 | 2/47 |
| Decreased platelet countBlood and lymphatic system disorders | 0/46 | 2/47 |
| CongestionRespiratory, thoracic and mediastinal disorders | 1/46 | 1/47 |
| DiarrheaGastrointestinal disorders | 1/46 | 0/47 |
| DizzinessNervous system disorders | 1/46 | 0/47 |
| DrowsinessNervous system disorders | 1/46 | 0/47 |
| FatigueGeneral disorders | 1/46 | 0/47 |
| Age, Categorical(Participants) | Chamomile Extract | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 40 | 42 | 82 |
| >=65 years | 6 | 5 | 11 |
| Age, Continuous(years) | Chamomile Extract | Placebo | Total |
|---|---|---|---|
| Mean | 49.2 ± 14.3 | 45.4 ± 16.1 | 47.3 ± 15.3 |
| Sex: Female, Male(Participants) | Chamomile Extract | Placebo | Total |
|---|---|---|---|
| Female | 34 | 31 | 65 |
| Male | 12 | 16 | 28 |
| Region of Enrollment(participants) | Chamomile Extract | Placebo | Total |
|---|---|---|---|
| United States | 46 | 47 | 93 |
Plan to share: No
The record gives a start of Feb 2010, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Matricaria recutita
Generalized Anxiety Disorder →